Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Oncology · Neuroendocrine Tumor

Why Do I Need a DOTATATE PET Scan for NETs?

At a Glance

A Ga-68 or Cu-64 DOTATATE PET scan is a specialized imaging test for neuroendocrine tumors that detects somatostatin receptors on tumor cells. It is superior to standard CT scans for finding hidden tumors, detecting early spread, and determining if a patient is eligible for PRRT treatment.

In this answer

5 sections

01

How Does a DOTATATE Scan Work?

02

Why Is It Better Than a CT or MRI?

03

Changing Your Treatment Plan

04

Important: Preparing for Your Scan

05

Do I Still Need Regular Scans?

When you have a neuroendocrine tumor (NET), your doctor will often order a Ga-68 DOTATATE PET scan in addition to, or instead of, standard CT and MRI scans. The reason is simple but critical: standard CT and MRI scans only show the physical size and shape of a tumor, while a DOTATATE PET scan targets the unique biology of NETs. This specialized scan acts like a molecular homing beacon, lighting up tiny tumors or metastases that regular scans would miss entirely.

(Note: Some hospitals use a slightly different tracer called Cu-64 DOTATATE (Copper-64). It works the exact same way and serves the identical purpose.)

How Does a DOTATATE Scan Work?

Neuroendocrine tumor cells frequently have specialized proteins on their surface called somatostatin receptors (specifically a type called SSTR2) [1][2]. You can think of these receptors as tiny locks.

In a DOTATATE scan, a safe, slightly radioactive tracer (Gallium-68 or Copper-64 combined with a compound called DOTATATE) is injected into your bloodstream through an IV. This tracer acts as the “key” that perfectly fits the somatostatin receptor “locks” [3][4]. When the tracer binds to the tumor cells, it emits a signal that the PET scanner picks up, making the tumors brightly visible [5].

What to Expect on Scan Day: The process is straightforward. After the IV injection, you will wait in a quiet room for about 45 to 60 minutes to allow the tracer to circulate and find the tumor cells. Then, you will lie flat in the PET/CT scanner for 30 to 45 minutes. The radiation dose is low and naturally leaves your body, mostly through your urine, within a day.

Why Is It Better Than a CT or MRI?

While conventional CT and MRI scans are important for seeing your anatomy and are routinely used in diagnosis and surveillance [6][7], they have limitations. A standard CT scan might miss a tumor if it is very small or if it blends in with surrounding healthy tissue.

Because it targets tumor biology rather than just physical size, a DOTATATE scan offers several distinct advantages:

  • Finding “Hidden” Tumors: It has superior sensitivity for finding the primary (original) tumor when its location is unknown [8][9].
  • Spotting Tiny Spread: It is much better at detecting very small metastases (spread) in places like the bones or lymph nodes that a regular CT or MRI would overlook [10][11][3].
  • Proving Tumor Biology: By showing how brightly the tumors light up, the scan proves exactly how many somatostatin receptors your tumors have [1][12]. This gives your doctors critical information about how your disease might behave [13].

(Note on Insurance: Because these scans are specialized and expensive, insurance companies sometimes push back, asking patients to “just do a CT first.” The medical evidence clearly shows that DOTATATE PET scans are superior for detecting NETs, which is often the key argument doctors use to prove the scan is a “medical necessity.”)

Changing Your Treatment Plan

The ability to see the disease so clearly often changes a patient’s medical management. Research shows that performing a DOTATATE scan frequently leads to adjustments in treatment plans [14][15].

For example:

  • Surgical Planning: Finding an unexpected spot of spread might change whether surgery is still the best option, or change the surgical approach itself [16].
  • Targeted Therapies: This scan is essential for determining if you are a candidate for Peptide Receptor Radionuclide Therapy (PRRT) [17][18]. PRRT works by using a similar “key” to deliver therapeutic radiation directly to the tumor cells. If your tumor does not light up on a DOTATATE scan, it means it lacks the necessary receptors, and PRRT will not work for you [19]. (Note: A positive scan means you are eligible for PRRT, but it does not necessarily mean you need it immediately; it simply becomes an option in your toolkit).

Important: Preparing for Your Scan

If you are currently taking a somatostatin analog (SSA) medication (such as octreotide or lanreotide) to control your symptoms or slow tumor growth, you must carefully time your scan around your injections.

Because these medications act as “keys” trying to fit into the exact same “locks” as the PET tracer, taking them too close to your scan day can block the tracer. This is called competitive binding, and it can cause a “false negative” scan where your tumors don’t light up. Typically, doctors schedule the PET scan right before your next long-acting monthly injection.

Do I Still Need Regular Scans?

Yes. DOTATATE scans do not completely replace CTs and MRIs. The best approach often combines these tools [20][21]. For instance, certain types of MRI are sometimes better at detailing specific liver metastases [22], while the DOTATATE PET maps the whole body.

Additionally, some NETs (like faster-growing Grade 3 tumors) may lose their somatostatin receptors over time, meaning they won’t light up as brightly on a DOTATATE scan. In those cases, other types of PET scans (like an FDG PET, which looks for cells rapidly consuming sugar instead of looking for receptors) or standard CTs are necessary to see the full picture [23][24].

Common questions in this guide

Why is a DOTATATE PET scan better than a standard CT or MRI for NETs?
While a standard CT or MRI only shows the physical size and shape of a tumor, a DOTATATE PET scan targets the specific biology of neuroendocrine tumors. It acts like a molecular homing beacon to highlight tiny tumors or spread that regular scans might completely miss.
How does a Ga-68 DOTATATE PET scan work?
A safe, slightly radioactive tracer is injected into your bloodstream, acting like a 'key' that fits perfectly into somatostatin receptor 'locks' on the surface of neuroendocrine tumor cells. The PET scanner then detects this tracer, making the tumors glow brightly on the image.
Can my monthly hormone injections interfere with my DOTATATE scan?
Yes, if you take somatostatin analogs like octreotide or lanreotide, they can block the PET tracer from binding to your tumor cells, causing a false negative result. You must carefully time your scan around your injections, usually scheduling it right before your next monthly dose.
How does a DOTATATE scan affect my eligibility for PRRT?
The scan proves whether your tumors have the specific somatostatin receptors needed for Peptide Receptor Radionuclide Therapy (PRRT) to work. If your tumors light up brightly on the scan, it means you are a potential candidate for this targeted radiation treatment.
Do I still need regular CT or MRI scans if I get a DOTATATE PET?
Yes, DOTATATE scans do not completely replace standard imaging. Doctors often combine these tools because certain MRIs are better at showing specific details like liver tumors, and standard scans are still needed to monitor faster-growing tumors that may lose their receptors over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my specific type and grade of neuroendocrine tumor typically have somatostatin receptors?
  2. 2.How exactly should I time my monthly symptom-control injections (like octreotide or lanreotide) around the date of this scan so the medication doesn't interfere with the results?
  3. 3.How did the results of my DOTATATE PET scan change or confirm your recommended treatment plan?
  4. 4.Based on the intensity of the uptake on my DOTATATE scan, am I a potential candidate for PRRT in the future?
  5. 5.My insurance is pushing back on the DOTATATE scan; can your office provide a letter of medical necessity explaining why a standard CT is insufficient for my case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are Endocrine Tumors Benign or Malignant?Are Endocrine Tumors Hereditary? Testing GuideWhat is a Carcinoid Crisis During Surgery?What Are the Symptoms of Carcinoid Syndrome?Endocrine Tumors: Why Do They Cause Weight Gain & High BP?What Foods to Avoid Before an Endocrine Tumor Test?What Is a Functional vs Non-Functional Endocrine Tumor?Will I Need Hormone Therapy After Gland Removal?Who Treats Endocrine Tumors? Your Care Team ExplainedNET vs. NEC Neuroendocrine Tumors: What's the Difference?How Does PRRT (Lutathera) Work for Neuroendocrine Tumors?Why Is Biopsy Dangerous for Suspected Pheochromocytoma?Why Does MEN2 Require Preventative Thyroid Surgery?Somatostatin Analogs (SSAs) for NETs: What to ExpectWhat is the Ki-67 Index in Neuroendocrine Tumors (NETs)?

References

References (24)
  1. 1

    Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.

    Roden AC, Rakshit S, Johnson GB, et al.

    Frontiers in oncology 2022; (12()):823667 doi:10.3389/fonc.2022.823667.

    PMID: 35198446
  2. 2

    Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.

    Yu J, Cao F, Zhao X, et al.

    Neuroendocrinology 2022; (112(4)):358-369 doi:10.1159/000517530.

    PMID: 34077939
  3. 3

    Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.

    Crown A, Rocha FG, Raghu P, et al.

    Journal of surgical oncology 2020; (121(3)):480-485 doi:10.1002/jso.25812.

    PMID: 31853990
  4. 4

    Enhancing Diagnostic Accuracy in Sinonasal Neuroendocrine Tumors: The Case for DOTATATE PET Over FDG PET.

    Sabbaj M, Kanwar A, Grayson JW, et al.

    International forum of allergy & rhinology 2025; (15(10)):1023-1027 doi:10.1002/alr.70001.

    PMID: 40679114
  5. 5

    Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies.

    Bodei L, Ambrosini V, Herrmann K, Modlin I

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1718-1726 doi:10.2967/jnumed.116.186361.

    PMID: 28818983
  6. 6

    ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.

    Sundin A, Arnold R, Baudin E, et al.

    Neuroendocrinology 2017; (105(3)):212-244 doi:10.1159/000471879.

    PMID: 28355596
  7. 7

    Imaging in neuroendocrine tumors: an update for the clinician.

    Maxwell JE, Howe JR

    International journal of endocrine oncology 2015; (2(2)):159-168 doi:10.2217/ije.14.40.

    PMID: 26257863
  8. 8

    68Ga DOTATATE PET/CT is an Accurate Imaging Modality in the Detection of Culprit Tumors Causing Osteomalacia.

    Zhang J, Zhu Z, Zhong D, et al.

    Clinical nuclear medicine 2015; (40(8)):642-6 doi:10.1097/RLU.0000000000000854.

    PMID: 26053726
  9. 9

    68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.

    El-Maouche D, Sadowski SM, Papadakis GZ, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(10)):3575-3581 doi:10.1210/jc.2016-2052.

    PMID: 27533306
  10. 10

    Ga-68 DOTATATE PET imaging in the management of head and neck paragangliomas: a potential game changer.

    Alduraibi A, Bin Essa N, Alruwaili AA, Bomanji J

    Frontiers in oncology 2025; (15()):1675974 doi:10.3389/fonc.2025.1675974.

    PMID: 41341385
  11. 11

    Comparison of the Sensitivity of 68 Ga-DOTATATE PET/CT with Other Imaging Modalities in Detecting Head and Neck Paraganglioma: Experience from Western India.

    Dodamani MH, Jaiswal SK, Sarathi V, et al.

    World journal of nuclear medicine 2022; (21(3)):184-191 doi:10.1055/s-0042-1751030.

    PMID: 36060084
  12. 12

    Somatostatin Receptor 2 Negative Pheochromocytoma Masked by Normal Adrenal Gland on Gallium-68 DOTATATE.

    Park SE, Hoang TD, Stocker DJ, et al.

    AACE clinical case reports 2025; (11(2)):134-137 doi:10.1016/j.aace.2024.12.011.

    PMID: 40201467
  13. 13

    Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT.

    Lee H, Kipnis ST, Niman R, et al.

    Cancers 2023; (16(1)) doi:10.3390/cancers16010200.

    PMID: 38201627
  14. 14

    The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas.

    Skoura E, Priftakis D, Novruzov F, et al.

    Nuclear medicine communications 2020; (41(2)):169-174 doi:10.1097/MNM.0000000000001130.

    PMID: 31895260
  15. 15

    Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors.

    Anderson RC, Velez EM, Desai B, Jadvar H

    Nuclear medicine and molecular imaging 2021; (55(1)):31-37 doi:10.1007/s13139-020-00677-0.

    PMID: 33643487
  16. 16

    The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.

    Skoura E, Michopoulou S, Mohmaduvesh M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016; (57(1)):34-40 doi:10.2967/jnumed.115.166017.

    PMID: 26471695
  17. 17

    Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

    Kandathil A, Subramaniam RM

    PET clinics 2023; (18(2)):189-200 doi:10.1016/j.cpet.2022.11.001.

    PMID: 36585339
  18. 18

    Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?

    Basu S, Ostwal V

    Nuclear medicine communications 2016; (37(6)):669-71 doi:10.1097/MNM.0000000000000507.

    PMID: 27105440
  19. 19

    68Ga-DOTATATE PET-CT imaging in carotid body paragangliomas.

    Şimşek DH, Şanlı Y, Kuyumcu S, et al.

    Annals of nuclear medicine 2018; (32(4)):297-301 doi:10.1007/s12149-018-1242-3.

    PMID: 29468487
  20. 20

    Neuroendocrine Tumors of Unknown Primary: A Review of the Diagnosis and Treatment.

    Murdock P, Humphreys B, Muscarella K, et al.

    The American surgeon 2026; (92(7)):1948-1955 doi:10.1177/00031348251393931.

    PMID: 41566902
  21. 21

    [Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology].

    Ebner R, Rübenthaler J, Ricke J, et al.

    Radiologie (Heidelberg, Germany) 2024; (64(7)):553-558 doi:10.1007/s00117-024-01296-y.

    PMID: 38713221
  22. 22

    Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection?

    Babazadeh NT, Schlund DJ, Cornelius T, et al.

    World journal of surgery 2020; (44(2)):604-611 doi:10.1007/s00268-019-05216-3.

    PMID: 31576440
  23. 23

    Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.

    Sanli Y, Garg I, Kandathil A, et al.

    AJR. American journal of roentgenology 2018; (211(2)):267-277 doi:10.2214/AJR.18.19881.

    PMID: 29975116
  24. 24

    Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.

    Hu X, Li D, Wang R, et al.

    Medicine 2023; (102(19)):e33726 doi:10.1097/MD.0000000000033726.

    PMID: 37171344

This page explains DOTATATE PET scans for educational purposes only. Always consult your oncologist or nuclear medicine specialist regarding your specific imaging schedule, medication timing, and treatment plan.

Get notified when new evidence is published on Tumor of endocrine glands.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.